Nifty
:
23587.50
Sensex
:
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)
Nifty
Sensex
:
:
23587.50
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
N/A

BSE: 539523 | NSE: ALKEM

NSE BSE
5427.50
20-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  5535.00
  •  5543.25
  •  5404.80
  •  5494.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  113105
  •  6185.37
  •  6439.90
  •  4407.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 64,945.91
  • 30.60
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 64,229.93
  • 0.74%
  • 5.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 55.66%
  • 0.12%
  • 15.85%
  • FII
  • DII
  • Others
  • 9.02%
  • 18.12%
  • 1.23%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.96
  • 8.71
  • 6.01

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.20
  • 8.79
  • 1.81

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.45
  • 9.76
  • 2.95

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.79
  • 28.54
  • 34.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.89
  • 5.02
  • 5.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.36
  • 20.43
  • 21.76

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
150.19
186.1
209.24
233.03
P/E Ratio
36.29
29.28
26.05
23.39
Revenue
12439
13324
14709
16134
EBITDA
2279
2595
2972
3432
Net Income
1796
2229
2513
2793
ROA
12.2
14.1
14.3
14.8
P/Bk Ratio
6.32
5.44
4.72
4.13
ROE
18.55
19.74
19.23
18.17
FCFF
1836.94
1741.09
1610.77
2100.8
FCFF Yield
2.8
2.65
2.45
3.2

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
3,414.67
3,440.17
-0.74%
3,031.82
2,967.72
2.16%
2,935.82
2,902.60
1.14%
3,323.87
3,040.91
9.31%
Expenses
2,661.84
2,693.44
-1.17%
2,423.18
2,578.53
-6.02%
2,533.84
2,549.35
-0.61%
2,616.28
2,441.86
7.14%
EBITDA
752.83
746.73
0.82%
608.64
389.19
56.39%
401.98
353.25
13.79%
707.59
599.05
18.12%
EBIDTM
22.05%
21.71%
20.08%
13.11%
13.69%
12.17%
21.29%
19.70%
Other Income
134.48
63.19
112.82%
120.31
65.84
82.73%
88.17
68.67
28.40%
93.64
45.33
106.57%
Interest
28.14
30.32
-7.19%
29.11
29.77
-2.22%
26.86
28.96
-7.25%
25.46
27.05
-5.88%
Depreciation
78.91
73.90
6.78%
80.48
72.41
11.14%
83.43
78.32
6.52%
69.56
78.44
-11.32%
PBT
780.26
648.04
20.40%
619.36
352.85
75.53%
367.34
211.66
73.55%
654.90
538.89
21.53%
Tax
78.30
33.15
136.20%
69.12
65.04
6.27%
62.86
143.98
-56.34%
50.62
78.93
-35.87%
PAT
701.96
614.89
14.16%
550.24
287.81
91.18%
304.48
67.68
349.88%
604.28
459.96
31.38%
PATM
20.56%
17.87%
18.15%
9.70%
10.37%
2.33%
18.18%
15.13%
EPS
57.60
51.90
10.98%
45.60
23.98
90.16%
24.56
5.94
313.47%
49.77
38.04
30.84%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
12,706.18
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
3,743.35
Net Sales Growth
2.87%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
31.56%
 
Cost Of Goods Sold
4,692.59
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
1,453.41
Gross Profit
8,013.59
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
2,289.94
GP Margin
63.07%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
61.17%
Total Expenditure
10,235.14
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
3,321.52
Power & Fuel Cost
-
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
53.31
% Of Sales
-
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
1.42%
Employee Cost
-
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
645.87
% Of Sales
-
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
17.25%
Manufacturing Exp.
-
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
367.58
% Of Sales
-
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
9.82%
General & Admin Exp.
-
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
238.92
% Of Sales
-
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
6.38%
Selling & Distn. Exp.
-
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
434.56
% Of Sales
-
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
11.61%
Miscellaneous Exp.
-
406.87
181.00
85.84
91.05
130.67
127.28
107.99
122.20
125.18
434.56
% Of Sales
-
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
3.42%
EBITDA
2,471.04
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
421.83
EBITDA Margin
19.45%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
11.27%
Other Income
436.60
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
181.04
Interest
109.57
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
81.11
Depreciation
312.38
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
70.94
PBT
2,421.86
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
Tax
260.90
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
59.23
Tax Rate
10.77%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
13.14%
PAT
2,160.96
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
391.59
PAT before Minority Interest
2,122.32
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
391.59
Minority Interest
-38.64
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
0.00
PAT Margin
17.01%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
10.46%
PAT Growth
51.08%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
89.38%
 
EPS
180.68
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01
32.74

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
2,999.05
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
2,975.14
Non-Current Liabilities
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
200.60
Secured Loans
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
33.43
Unsecured Loans
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
0.00
Long Term Provisions
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
66.58
Current Liabilities
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
2,005.98
Trade Payables
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
465.93
Other Current Liabilities
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
366.01
327.06
Short Term Borrowings
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
1,128.57
Short Term Provisions
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
84.42
Total Liabilities
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
Net Block
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
1,374.34
Gross Block
4,543.70
4,050.24
4,185.64
3,768.89
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
1,744.89
Accumulated Depreciation
1,629.36
1,367.39
1,283.91
975.91
698.94
495.64
320.19
180.16
89.10
370.55
Non Current Assets
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
2,953.23
Capital Work in Progress
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
110.69
Non Current Investment
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
419.73
Long Term Loans & Adv.
203.74
139.07
154.44
93.77
98.16
118.64
141.37
193.07
142.35
542.17
Other Non Current Assets
78.60
274.70
697.18
48.55
46.68
46.65
92.42
405.83
251.03
506.30
Current Assets
10,411.58
8,606.42
8,433.70
6,928.82
5,505.65
4,216.13
4,013.22
2,917.14
2,768.70
2,338.05
Current Investments
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
61.05
Inventories
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
784.23
Sundry Debtors
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
527.08
Cash & Bank
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
790.76
Other Current Assets
3,769.25
244.68
239.80
335.19
775.37
578.37
567.93
304.68
236.74
174.93
Short Term Loans & Adv.
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
114.85
Net Current Assets
6,417.03
4,899.27
3,628.36
3,324.77
2,261.07
1,998.60
1,629.91
1,227.45
1,231.10
332.07
Total Assets
14,060.07
12,330.89
12,758.20
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
325.47
PBT
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
450.82
Adjustment
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
-7.82
Changes in Working Capital
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
-11.89
Cash after chg. in Working capital
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
431.11
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
-105.64
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
-236.97
Net Fixed Assets
-74.10
-101.58
-254.26
-139.76
-310.63
-342.15
-531.27
-390.07
160.79
-111.90
Net Investments
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
-129.77
Others
-1,110.97
691.36
-804.64
-662.44
-170.28
176.86
200.90
464.11
128.59
4.70
Cash from Financing Activity
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
-51.78
Net Cash Inflow / Outflow
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
36.72
Opening Cash & Equivalents
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
100.82
Closing Cash & Equivalent
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05
139.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
250.86
ROA
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
8.16%
ROE
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
14.03%
ROCE
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
13.27%
Fixed Asset Turnover
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
2.65
Receivable days
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
42.27
Inventory Days
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
66.41
Payable days
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
45.83
Cash Conversion Cycle
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
62.85
Total Debt/Equity
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
0.44
Interest Cover
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03
6.56

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Alkem Laboratories to make equity investment in Sunsure Solarpark
    18th Dec 2024, 11:43 AM

    The said investment will be completed by the end of April, 2025

    Read More
  • Alkem Laboratories gets nod to transfer trade generics business to M/s. Alkem Wellness
    10th Dec 2024, 14:27 PM

    The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same

    Read More
  • Alkem Laboratories signs licensing agreement with Sonnet BioTherapeutics Holdings
    10th Oct 2024, 15:50 PM

    The licensing agreement is to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India

    Read More
  • Alkem Laboratories incorporates wholly owned subsidiary
    17th Sep 2024, 11:59 AM

    Alkem Wellness has been incorporated to carry on the business in all kinds of drugs, pharmaceuticals, drugs formulation, etc

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.